Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Drug Review Costs Rise, But Personnel Spending Flattens

Executive Summary

Less than 60% of the total spending on reviews was attributed to employee compensation and benefits in FY 2011. FDA says it is normal, but the figure is lower than costs seen in recent years.

You may also be interested in...



Lower Costs For Drug Review Personnel Are “Completely Normal” – FDA

While personnel costs fall in human drug reviews, non-personnel expenses increase. The changes could indicate FDA cost containment, but also come with another user fee increase.

Lower Costs For Drug Review Personnel Are “Completely Normal” – FDA

While personnel costs fall in human drug reviews, non-personnel expenses increase. The changes could indicate FDA cost containment, but also come with another user fee increase.

Drug Review Personnel Costs Dropping, Remain “Completely Normal,” FDA Says

Decrease is part of a trend of increasing non-personnel expenses related to human drug review, which may indicate FDA cost containment, but also comes with another user fee increase.

Related Content

Topics

UsernamePublicRestriction

Register

PS054670

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel